- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
FDA Grants Orphan Drug Designation to Thrombotic Thrombocytopenic Purpura Drug
GC1126A is designed to treat the rare blood disorder.
GC Biopharma Corp. announced that GC1126A has been granted orphan drug designation by FDA. This will provide certain incentives, such as tax credits for clinical development costs.
The drug is a treatment for Thrombotic Thrombocytopenic Purpura, a rare and life-threatening blood disorder that can cause the formation of small blood clots.
GC1126A is designed to evade antibodies, providing it with a longer half-life within the body.
In a press release, a spokesperson for GC Biopharma said, “We are dedicated to collecting data to develop a Best-in-Class treatment for such rare disorders. We remain committed to our mission of providing patients with new treatment options by continuously developing innovative drugs."
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
